Sorrento Therapeutics Higher

Sorrento Therapeutics rose more than 12% after the company said its lead investigational product, ZTlido has demonstrated superior adhesion versus the EU reference product Versatis during a recently completed comparative adhesion performance study.

These data complement a previous clinical adhesion study performed to support the new drug application (NDA) submission for ZTlido in the US, where greater than 90% of the subjects demonstrated greater than 90% adhesion over the 12-hour administration period using the FDA recommended 5-point scale, it said. ZTlid is a non-opioid, lidocaine patch currently in development for the treatment of post-herpetic neuralgia, a severe neuropathic pain condition, the company said.

Leave a Comment